hotspot -WSS

hotspot

author：knowledge 2025-10-01 22:49:37 - browse：1237

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

explore

focus

WSS

FDA poised to publish guidelines for clinical trial diversity

H5N1 virus can be tracked in retail milk, scientists say

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

Pharma needs to include young adults in clinical research

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

California Joshua trees severely burned in massive wildfire

entertainment

hotspot

knowledge

Medicare details structure of new drug price negotiation program

Russian court extends detention of American musician

After affirmative action ruling, medical educators look to 'holistic review'

Biogen joins immunology wave with $1.15 billion acquisition of HI

The high cost of giving birth even with insurance

Listen: More tumult at BIO & coercive care for sickle cell patients

State Dept. review finds Biden bears some blame for Afghanistan failures

Parkland mass shooting to be reenacted for lawsuit

How to save PrEP access — and even expand it

Digital health: a case of mistaken identity

Wikipedia

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

Pharma needs to include young adults in clinical research

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Lifetime voting ban for felony convictions struck down in Mississippi

explore

explore

focus

entertainment